These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 34995678)

  • 1. Nanovaccines with cell-derived components for cancer immunotherapy.
    Meng Z; Zhang Y; Zhou X; Ji J; Liu Z
    Adv Drug Deliv Rev; 2022 Mar; 182():114107. PubMed ID: 34995678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance.
    Xu Z; Zhou H; Li T; Yi Q; Thakur A; Zhang K; Ma X; Qin JJ; Yan Y
    Drug Resist Updat; 2024 Jul; 75():101098. PubMed ID: 38833804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unlocking the power of nanomedicine: Cell membrane-derived biomimetic cancer nanovaccines for cancer treatment.
    Zhao G; Wang S; Nie G; Li N
    Med; 2024 Jul; 5(7):660-688. PubMed ID: 38582088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
    Aikins ME; Xu C; Moon JJ
    Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole-Cell Components of Tumor Tissues or Cells.
    Ma L; Diao L; Peng Z; Jia Y; Xie H; Li B; Ma J; Zhang M; Cheng L; Ding D; Zhang X; Chen H; Mo F; Jiang H; Xu G; Meng F; Zhong Z; Liu M
    Adv Mater; 2021 Oct; 33(43):e2104849. PubMed ID: 34536044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanovaccines: Immunogenic tumor antigens, targeted delivery, and combination therapy to enhance cancer immunotherapy.
    Jahanafrooz Z; Oroojalian F; Mokhtarzadeh A; Rahdar A; Díez-Pascual AM
    Drug Dev Res; 2024 Aug; 85(5):e22244. PubMed ID: 39138855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanovaccines: An effective therapeutic approach for cancer therapy.
    Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH
    Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
    Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
    Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologically Self-Assembled Tumor Cell-Derived Cancer Nanovaccines as an All-in-One Platform for Cancer Immunotherapy.
    Liang K; Sun Y; Xie L; Liu Y; You Y; Xu J; Ma F; Huang Y; Song Q; Xiao W; Huang J; Gao X; Chen J
    ACS Nano; 2024 Feb; 18(8):6702-6717. PubMed ID: 38359389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leveraging Senescent Cancer Cell Membrane to Potentiate Cancer Immunotherapy Through Biomimetic Nanovaccine.
    Yang C; Chen Y; Liu J; Zhang W; He Y; Chen F; Xie X; Tang J; Guan S; Shao D; Wang Z; Wang L
    Adv Sci (Weinh); 2024 Aug; 11(30):e2400630. PubMed ID: 38867377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanobiomaterial-based vaccination immunotherapy of cancer.
    Chen F; Wang Y; Gao J; Saeed M; Li T; Wang W; Yu H
    Biomaterials; 2021 Mar; 270():120709. PubMed ID: 33581608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy.
    Pan Y; Wu X; Liu L; Zhao C; Zhang J; Yang S; Pan P; Huang Q; Zhao XZ; Tian R; Rao L
    Adv Healthc Mater; 2024 May; 13(13):e2400068. PubMed ID: 38320299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell-based nanovaccines for cancer immunotherapy.
    Paulis LE; Mandal S; Kreutz M; Figdor CG
    Curr Opin Immunol; 2013 Jun; 25(3):389-95. PubMed ID: 23571027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy.
    Cai T; Liu H; Zhang S; Hu J; Zhang L
    J Nanobiotechnology; 2021 Nov; 19(1):389. PubMed ID: 34823541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manganese oxide-constructed multifunctional biomimetic nanovaccine for robust tumor-specific T cell priming and chemodynamic therapy.
    Li T; Chen G; Lin L; Li B; Wang X; Chen Y; Huang W; Cai M; Xiao Z; Shuai X; Zhu K
    Biomaterials; 2024 Sep; 309():122626. PubMed ID: 38795524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanovaccine-Based Strategies to Overcome Challenges in the Whole Vaccination Cascade for Tumor Immunotherapy.
    Qin L; Zhang H; Zhou Y; Umeshappa CS; Gao H
    Small; 2021 Jul; 17(28):e2006000. PubMed ID: 33768693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomimetic nanoparticles for DC vaccination: a versatile approach to boost cancer immunotherapy.
    Meng L; Teng Z; Yang S; Wang N; Guan Y; Chen X; Liu Y
    Nanoscale; 2023 Apr; 15(14):6432-6455. PubMed ID: 36916703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor associated antigens combined with carbon dots for inducing durable antitumor immunity.
    Liu H; Zhang T; Zheng M; Xie Z
    J Colloid Interface Sci; 2024 Nov; 673():594-606. PubMed ID: 38897061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
    Zhu G; Zhang F; Ni Q; Niu G; Chen X
    ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-adjuvanting cancer nanovaccines.
    Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
    J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.